Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction

JACC: Heart Failure

Volumn 4, Issue 5, 2016, Pages 392-402

  King, Jordan B ^a   Shah, Rashmee U ^b   Bress, Adam P ^a   Nelson, Richard E ^b,c   Bellows, Brandon K ^a,d  

^a UNIVERSITY OF UTAH   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d SelectHealth Inc   (United States)

Author keywords

Angiotensin inhibition; Cost utility; LCZ696; Neprilysin inhibition

Indexed keywords

ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MEMBRANE METALLOENDOPEPTIDASE; TETRAZOLE DERIVATIVE;

ADULT; AGE; AGED; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL COST; HOSPITAL READMISSION; HUMAN; MAJOR CLINICAL STUDY; MARKOV CHAIN; MEDICAL DECISION MAKING; MIDDLE AGED; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEART STROKE VOLUME; HOSPITALIZATION; MALE; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; ENALAPRIL; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; NEPRILYSIN; QUALITY-ADJUSTED LIFE YEARS; STROKE VOLUME; TETRAZOLES;

EID: 84962086839     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2016.02.007     Document Type: Article

References (36)

1. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987, 316:1429-1435. The CONSENSUS Trial Study Group.
2. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991, 325:293-302. The SOLVD Investigators.
3. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999, 353:2001-2007. MERIT-HF Study Group.
4. Cohn J.N., Fowler M.B., Bristow M.R., et al. Safety and efficacy of carvedilol in severe heart failure. J Card Fail 1997, 3:173-179. for the U.S. Carvedilol Heart Failure Study Group.
5. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675. for the Valsartan Heart Failure Trial Investigators.
6. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
7. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999, 341:709-717. for the Randomized Aldactone Evaluation Study Investigators.
8. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626. for the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators and Committees.
9. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21. for the EMPHASIS-HF Study Group.
10. McMurray J.J., Packer M., Desai A.S., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014, 371:993-1004. for the PARADIGM-HF Investigators and Committees.
11. King J.B., Bress A.P., Reese A.D., Munger M.A. Neprilysin inhibition in heart failure with reduced ejection fraction: a clinical review. Pharmacotherapy 2015, 35:823-837.
12. Anderson J.L., Heidenreich P.A., Barnett P.G., et al. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. J Am Coll Cardiol 2014, 63:2304-2322.
13. Cohen D.J., Reynolds M.R. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol 2008, 52:2119-2126.
14. Arias E., Heron M., Tejada-Vera B. United States life tables eliminating certain causes of death, 1999-2001. Natl Vital Stat Rep 2013, 61:1-128.
15. Packer M., McMurray J.J., Desai A.S., et al. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation 2015, 131:54-61. on behalf of the PARADIGM-HF Investigators and Committees.
16. Bress A.P., King J.B., Brixner D., et al. Pharmacotherapy treatment patterns, outcomes, and health resource utilization among patients with heart failure with reduced ejection fraction at a U.S. academic medical center. Pharmacotherapy 2016, 36:174-186.
17. Ford E., Adams J., Graves N. Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia. BMJ Open 2012, 2:e001094.
18. Yao G., Freemantle N., Flather M., Tharmanathan P., Coats A., Poole-Wilson P.A. Long-term cost-effectiveness analysis of nebivolol compared with standard care in elderly patients with heart failure: an individual patient-based simulation model. Pharmacoeconomics 2008, 26:879-889. SENIORS Investigators.
19. Flather M.D., Shibata M.C., Coats A.J., et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005, 26:215-225.
20. Calvert M.J., Freemantle N., Yao G., et al. Cost-effectiveness of cardiac resynchronization therapy: results from the CARE-HF trial. Eur Heart J 2005, 26:2681-2688.
21. Micromedex Healthcare Series. Red Book Online. 2015. Available at: . Accessed March 21, 2015. http://micromedex.com/products/product-suites/clinical-knowledge/redbook.
22. U.S. Bureau of Labor Statistics. Consumer Price Index, 2015. Available at: . Accessed March 2015. http://www.bls.gov/cpi.
23. Desai A.S., McMurray J.J.V., Packer M., et al. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 2015, 36:1990-1997.
24. Solomon S. Reduction in 30-day all-cause rehospitalization after discharge from a heart failure admission in patients receiving entresto versus enalapril: PARADIGM-HF [oral presentation]. Presented at: American Heart Association Scientific Sessions; November 7-11, 2015; Orlando, FL.
25. Thokala P., Baalbaki H., Brennan A. Telemonitoring after discharge from hospital with heart failure: cost-effectiveness modelling of alternative service designs. Value Health 2013, 16:A530.
26. Centers for Medicare & Medicaid Services. Pharmacy drug pricing: January 2016 NADAC. Available at: . Accessed January 23, 2016. https://www.medicaid.gov/Medicaid-CHIP-Program-Information/By-Topics/Benefits/Prescription-Drugs/Pharmacy-Pricing.html.
27. Walmart. $4 Prescription Program. 2008. Available at: . Accessed March 2015. http://i.walmart.com/i/if/hmp/fusion/four_dollar_drug_list.pdf.
28. Millier A, Briquet B, Aballea S, Toumi M. Should changes in drug price over time be considered in cost-effectiveness analyses? Abstract presented at: 17th Annual European Congress of the International Society of Pharmacoeconomics and Outcomes Research; November 2014; Amsterdam, the Netherlands.
29. Centers for Medicare & Medicaid Services. FY 2015 final rule data files: FY 2015 impact file. Available at: . Accessed March 10, 2015. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/FY2015-IPPS-Final-Rule-Home-Page-Items/FY2015-Final-Rule-Data-Files.html?DLPage=1&DLEntries=10&DLSort=0&DLSortDir=ascending.
30. Claggett B., Packer M., McMurray J.J.V., et al. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med 2015, 373:2289-2290. for the PARADIGM-HF Investigators.
31. Neumann P.J., Cohen J.T., Weinstein M.C. Updating cost-effectiveness: the curious resilience of the $50,000-per-QALY threshold. N Engl J Med 2014, 371:796-797.
32. Weinstein M.C. How much are Americans willing to pay for a quality-adjusted life year?. Med Care 2008, 46:343-345.
33. Simpson J., Jhund P.S., Silva Cardoso J., et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF. J Am Coll Cardiol 2015, 66:2059-2071.
34. Institute for Clinical and Economic Review. CardioMEMS™ HF System (St. Jude Medical) and Sacubitril/Valsartan (Entresto™, Novartis) for management of congestive heart failure: effectiveness, value, and value-based price benchmarks. Available at: . Accessed October 21, 2015. http://ctaf.org/sites/default/files/u148/CHF_Revised_Draft_Report_100915.pdf.
35. Pollack A. F.D.A approves heart drug entresto said to cut death risk by 20%. The New York Times. July 7, 2015. Available at: . Accessed July 21, 2015. http://www.nytimes.com/2015/07/08/business/international/fda-approves-heart-drug-entresto-after-promising-trial-results.html?_r=0.
36. Hirschler B. Novartis to test new pricing model with heart failure drug. June 30, 2015. Thomson Reuters. Available at: . Accessed July 21, 2015. http://www.reuters.com/article/2015/06/30/us-novartis-heart-idUSKCN0PA1N720150630?irpc=932.